Therefore, detecting and validating the use of molecular classification in precancerous lesions or analyzing different molecular markers could change therapeutic strategy, increasing the follow up of fertility-sparing patients or tailoring surgical radicality, reserving demolition surgery only for patients at high risk of cancer progression. Furthermore, EC generally affects patients with a higher rate of comorbidity, elderly or obese, the assessment of the state of women's frailty is fundamental to customize treatment strategies and reducing the morbidity rate therapy-related [[27], [29]]. To date, only advanced or metastatic stages could benefit from targeted adjuvant therapies based on molecular alterations, particularly considering advanced MSI-H/MMR-deficient (dMMR), numerous studies have evaluated the efficacy of monoclonal antibody therapy directed against immune checkpoint-associated proteins, expressed at high levels within the tumor microenvironment and making tumor cells susceptible to immune system response [[24]]. Considering the strong scientific evidence and the results we will obtain in ongoing studies, in recent years, EC therapy is increasingly becoming tailored for the various subclasses even if no level A evidence has supported the use of mutational and genomic profiling in the selection of adjuvant treatments in patients with early-stage disease. [Extracted from the article]